No Data
No Data
Rallybio Participates in a Conference Call With JPMorgan
Rallybio Presents Data Demonstrating ENPP1 Inhibition As A Therapeutic Approach For Later-Onset Hypophosphatasia Presented At The American Society For Bone And Mineral Research 2024 Annual Meeting
Dr. Kush Parmar Steps Down From Rallybio's Board and Committee
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
H.C. Wainwright Maintains Rallybio(RLYB.US) With Buy Rating, Maintains Target Price $6
No Data
No Data